Mark D Pankau
YOU?
Author Swipe
View article: Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering Open
Background Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformational outcomes in the treatment of B-cell malignancies, but their widespread use is hindered by technical and logistical challenges associated with ex…
View article: Association Between Cytomegalovirus and Epstein-Barr Virus Viremia And Human Immunodeficiency Virus DNA Levels in the Reservoir of Kenyan Infants Receiving Antiretroviral Therapy
Association Between Cytomegalovirus and Epstein-Barr Virus Viremia And Human Immunodeficiency Virus DNA Levels in the Reservoir of Kenyan Infants Receiving Antiretroviral Therapy Open
Identifying determinants of human immunodeficiency virus (HIV) reservoir levels may inform novel viral eradication strategies. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) coinfections were assessed as predictors of HIV proviral DNA …
Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women Open
View article: Dynamics of the HIV-1 Latent Reservoir
Dynamics of the HIV-1 Latent Reservoir Open
View article: Decay of HIV DNA in the Reservoir and the Impact of Short Treatment Interruption in Kenyan Infants
Decay of HIV DNA in the Reservoir and the Impact of Short Treatment Interruption in Kenyan Infants Open
We compared change in HIV reservoir DNA following continued antiretroviral therapy (ART) vs short treatment interruption (TI) in early ART-treated Kenyan infants. While HIV DNA in the reservoir decayed with continued ART, HIV DNA levels we…